Lexeo Therapeutics Acquired Mantle Therapeutics

The $8.3 million acquisition adds four assets targeting Friedreich's ataxia to Lexeo's clinical pipeline.

Updated on Sept. 22, 2026 in Biotech

Bold flat-color editorial illustration of a gene-therapy vial and pipette, representing biotechnology industry acquisition. — Lexeo Therapeutics has acquired Mantle Therapeutics in a deal worth up to $21.3 million to expand its pipeline of treatments for Friedreich's ataxia. AI Illustration. Upload story photo >

Live Poll

Do you believe biotech firms should prioritize the development of rare disease therapies?

Lexeo Therapeutics has acquired Mantle Therapeutics for an upfront payment of $8.3 million, with a total deal value potentially reaching $21.3 million. The transaction provides Lexeo with four new assets for the treatment of Friedreich's ataxia.

Why it matters

This acquisition expands Lexeo's portfolio of Friedreich's ataxia therapies, targeting a rare genetic condition that affects one in 50,000 people in the U.S. and often leads to cardiomyopathy in 80% of patients.

Early clinical data for the acquired oral therapy LX3010 demonstrated a 6-point improvement in the modified Friedreich's Ataxia Rating Scale (mFARS), which measures disease severity on a scale of 0 to 93.

The players

Lexeo Therapeutics

A clinical-stage biotechnology company focused on genetic medicine and treatments for cardiovascular and CNS disorders.

Mantle Therapeutics

A biotechnology firm specializing in the development of therapeutic assets for Friedreich's ataxia.

Weill Cornell Medicine

An academic medical center engaged in biomedical research and collaborative clinical development.

The details

The acquisition includes assets intended to support sequential dosing and central nervous system-targeted strategies for Friedreich's ataxia, a progressive neurodegenerative disorder. Lexeo plans to utilize these to bolster its platform while maintaining a cash runway through 2028. The company has also established strategic research and option agreements with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy.

April 2025: Lexeo laid off 15% of its staff.
August 2026: Lexeo initiated a pivotal study for LX2006.
September 2026: Lexeo announced the acquisition of Mantle Therapeutics.
Early 2027: Lexeo plans to provide a program prioritization.
2027: Lexeo plans to submit an IND for a new development candidate.

The Tech Race

This acquisition integrates new Friedreich's ataxia candidates alongside Lexeo's existing LX2006 program, which entered a pivotal study in August 2026. The move shifts the company's research trajectory toward a diversified approach combining oral therapies with gene-targeted interventions.

The clinical expansion of these Friedreich's ataxia assets does not provide immediate patient access, as treatments remain in development and trial stages. Future availability for patients depends on the success of the 2027 IND submission and subsequent clinical validation.

The takeaway

Lexeo is aggressively scaling its Friedreich's ataxia platform despite previous internal workforce reductions in 2025. Stakeholders should monitor the 2027 program prioritization to see which of the newly acquired assets move into active clinical development.

What happens next

Lexeo plans to provide a formal program prioritization in early 2027, followed by an IND submission for a new FA development candidate later that year and a topline data readout for LX2006 in the second half of 2027.